Q-omics provides the consensus-scored SH3BGR profile across patient tissues and cancer cell-line models. SH3BGR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SH3BGR is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SH3BGR RNA expression shows 18,074 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, KIRC, and UVM as cancer lineages where SH3BGR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH3BGR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH3BGR survival associations across molecular data types. SH3BGR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH3BGR RNA expression–survival associations across cancer types. High SH3BGR expression shows unfavorable associations in LGG, UVM and HNSC, but favorable associations in MESO, ACC and SARC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SH3BGR RNA expression.
This table summarizes SH3BGR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SH3BGR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH3BGR shows lower tumor expression in KIRC, BLCA, THCA, COAD, KIRP and HNSC. The KIRC box plot shows higher SH3BGR RNA expression in normal versus tumor tissue (log2 FC = −0.878, t-test p < 0.001).
This table shows molecular features associated with SH3BGR in patient tissues and cancer cell lines. In patient samples, SH3BGR shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SH3BGR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
